Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 387-394 , September 2009

The blast phase of chronic myeloid leukaemia

  • Richard T. Silver, MD, FACP (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 212 746 2856; Fax: +1 212 746 8246.

References 

  1. Karanas A, Silver RT. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968;32:445
  2. Kantarjian H, O'Brien S, Cortes J, et al. Sudden onset of the blastic phase of chronic myelogeneous leukemia: patterns and implications. Cancer. 2003;98:81–85
  3. Jabbour E, Kantarjian H, O'Brien S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006;107:480–482
  4. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–1432
  5. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytologic responses in patients with chronic myelogeneous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530–3539
  6. Vardiman JW, Harris NL, Bruning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  7. Cortes JE, O'Brien S, Garcia-Manero G, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979–1988
  8. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl 1-Positive chronic myeloid leukemia. Blood. 2009;113:1619–1630
  9. Cortes J, Silver RT, Kantarjian H. Chronic myeloid leukemia in Holland-Frei. Medicine Cancer. 2006;7:1761–1771edited by Kufe DW, Bast RC, Hait WN, et al., BC Decker, Inc., Hamilton, London
  10. Takahashi N, Miura I, Saito HK, et al. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting progressives in situ hybridization. Blood. 1998;92:4758–4763
  11. Bain B, Catovsky D, O'Brien M, et al. Megakaryoblastic transformation of chronic granulocytic leukemia. An electron microscopy and cytochemical study. J Clin Pathol. 1977;30:235–242
  12. Rosenthal S, Cancellos GP, Gralnick HP. Erythroblastic transformation of chronic granulocytic leukemia. Am J Med. 1977;63:116–124
  13. Mughal T, Cortes J, Cross NC, et al. Chronic myeloid leukemia—some topical issues. Leukemia. 2007;7:1347–1352
  14. Feinstein E, Cimino G, Gale RP, et al. P53 in chronic myelogeneous leukemia in acute phase. Proc Natl Acad Sci U S A. 1991;88:6293–6297
  15. Sill H, Goldman JM, Cross NC. Homozygous deletions of the P16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85:2013–2016
  16. Cross NCP, Daley GQ, Green AR, et al. BCR-ABL 1-positive CML and BCR-ABL 1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008;22:1975–1989
  17. Mughal TI, Goldman JL. Chronic myeloid leukemia: Why does it evolve from chronic phase to blastic transformation?. Front Biosci. 2006;11:198–278
  18. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–667
  19. Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica. 2008;93:1765–1769
  20. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103:2794
  21. Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia. 2006;20:1028–1034
  22. Hayes DM, Ellison RR, Glidwell O, et al. Chemotherapy for the terminal phase of chronic myelocytic leukemia. Cancer Chemotherapy Rep Part 2. 1974;4:233–247
  23. Coleman M, Silver RT, Pajak TF, et al. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood. 1980;55:29–36
  24. Dutcher JP. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogeneous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia. 1992;6:770–775
  25. Kantarjian H, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2′ deoxycytidine) therapy in 130 patients with chronic myelogeneous leukemia. Cancer. 2003;98:522–528
  26. Dutcher JP, Lee S, Paietta E, et al. Phase II study of carboplatinin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group study E1992. Leukemia. 1998;12:1037–1040
  27. Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol. 1993;11:2002–2009
  28. Giles FJ, Garcia-Manero G, Cortes JE, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog in patients with refractory leukemia. J Clin Oncol. 2002;20:656–664
  29. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogeneous leukemia in late chronic phase. Blood. 1995;86:3322–3326
  30. Bauduer F, Delmer A, Blanc M, et al. Treatment of chronic myelogeneous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. Leuk Lymphoma. 1993;10:195–200
  31. Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med. 1986;315:pp. 1433–1438
  32. Thomas ED, Cliff RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogeneous leukemia. Ann Intern Med. 1986;104:155–163
  33. Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996;3:S7–S9
  34. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (LCP), accelerated phase (AP), or blast crisis (BC), chronic myeloid leukemia (CML) treated with imatinib in three large Phase II trials. Blood. 2004;104:123
  35. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with Imatinib 600mg: Outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93:1792–1796
  36. Silver RT, Cortes J, Waltzman R, et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009;94:743–744
  37. O'Hare T, Walters DK, Stoffregen EP, et al. In Vitro activity of Bcr-Abl inhibitors AMN107 & BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505
  38. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399–401
  39. Cortes J, Jabbour E, Kantarjian H, et al. The dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;7:4005–4011
  40. Giles F, le Coutre P, Bhalla K, et al. A phase II study of nilotinib administered to patients with imatinib resistance or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib. ASCO Annual Meeting Proceedings Part I J Clin Oncol. 2007;25(18S):7038;[abstract]
  41. Kantarjian H, Giles F, Gutterman N, et al. Nilotinib (formerly AMN107) A highly selective BCR-ABL tyrosine kinase inhibitor is effective in patients with Philadelphia chromosome-positive chronic myelogeneous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540–3546
  42. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110:2828–2837
  43. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999 Sep 1;94:1517–1536
  44. Atallah E, Kantarjian H, deLima M, et al. The role of dasatinib in patients with Philadelphia positive acute lymphocytic leukemia (ALL) and chronic myeloid leukema (CML) relapsing after stem cell transplantation (SCT). Blood. 2006;108:[abstract 4120]
  45. Quintas-Cardama A, Cortes J. Kinase inhibitors in chronic myelogeneous leukemia. Clin Adv Hematol Oncol. 2006;4:365–373

PII: S1521-6926(09)00039-5

doi: 10.1016/j.beha.2009.07.006

Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 387-394 , September 2009

Article Tools